CA1112567A - Disodium cromoglycate self-propelling compositions - Google Patents
Disodium cromoglycate self-propelling compositionsInfo
- Publication number
- CA1112567A CA1112567A CA307,480A CA307480A CA1112567A CA 1112567 A CA1112567 A CA 1112567A CA 307480 A CA307480 A CA 307480A CA 1112567 A CA1112567 A CA 1112567A
- Authority
- CA
- Canada
- Prior art keywords
- sorbitan
- propellant
- composition according
- weight
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
COMPOSITION
ABSTRACT
Dispersions or suspensions of lecithin or a sorbitan or sorbitol ester in propellant 12, the dispersions or suspension containing no propellant 11 are described. The use of the dispersions in pressure pack formulations of medicaments is also described.
ABSTRACT
Dispersions or suspensions of lecithin or a sorbitan or sorbitol ester in propellant 12, the dispersions or suspension containing no propellant 11 are described. The use of the dispersions in pressure pack formulations of medicaments is also described.
Description
Ol/C/244 This invention relates to novel pressure-pack formulations of fine powders.
~- Leci~hin and various esters, notably sorbitan esters, e.g.
sorbitan oleates such as sorbitan sesquioleate ('Arlacel C'~*
sorbitan mono-oleate ~'Span 80')*and sorbitan trioleate ('Span 85')*, - sorbitan monolaurate3 polyoxyethylene sor~itol pentaoleate and polyoxyethylene sorbitol tetraoleate, have for some tirr.e been ;- known as surfactants fo~ use in pressure pack formulations ofmaterials and in particular for use in pressure pack formulations of finely divided medicaments. The formulation of these surfactants ., .
has invol~ed the use of p~opellant 11 (trichloromonofluoromethane).
Propellznt 11 has h~rever certain undesirable properties. The common practice in pressure pack nanufactu~e is to make a so called 'concentrate' or 'nucleus suspension' of the compound to be dispensed, e.g. the medicament, and one of the above surfactants ,-: . . .
in either propellant 11 or propellant 114 (1,2-dichloro-1,1,2~2-tctrafluoroethane). These concentrates may, because of the relatively high boiling point of the propellants, be handled at, or just bel~.Y~ ~oom temperature. It has however been found that lecithin and the esters mentioned above are extremely difficult to disperse in propellant114 and ~hese surfactants have therefore been dispersed in propellant 11. Other propellants of lower `~ boiling point have not been used because these surfactants ~ould not dissolve in these other propellants at the tow temperatures *trade mark ' 1 , ~
6'7 involved and furthermore would be solid at these low tempera~ures.
We have now found that lecithin and the above esters can be made into stable dispersions in propellant 12 (dichlorodifluoro-methane).
According to our invention ~e provide a dispersion or suspension of lecithin or a sorbitan or sorbltol ester in propellant 12, the dispersion or suspension containing substantially no propellant 11.
The dispersion may, if desired contain up to 25~ by weight of propellant 114, but preferably oontains no propellants other than ,: .
propellant 12.
The dispersion may be made by adding the lecithin or the - sorbitan or sorbitol ester to the propellant 12 ~or to a mixture of propellants 12 and 114) at a temperature of below about -30C, e.g. at 40C, using a high dispersion mixer. The dispersion .i.
- 15 preferably comprises less than ~.0%, e.g. from 0.2 to 2.0~ w/w of the leicithin or of the sorbitan or sorbitol ester. In ma~ing the suspension the surfactan~ solidifies, but is readily dispersed as small discrete particles in the propellant 12 tor the mixture of propellants 12 and 114). The resulting dispersions are usually stable for at least 30 minutes.
The dispersion of the surfactant m the propellant lZ ~or the mixture of propellants 12 and 1143 can be mixed wnth the finely divided material which it is desired to dispense ~rom the pressure pack. Suitabi~ ~mely di~ided materials include medicaments and notably inhalation medicaments, e.g. bronchodilators such as '' .
'7 isoprenaline, orciprenaline, terbutalene, rimiterol, fenoterol, carbutarol or salbutamol or a pharmaceutically acceptable salt of any one the~eof; topical steroids such as beclomethasone dipropionate, betamethasone valerate or triamcinolone acetonide;
- S and compounds which prevent the release of mediators of anaphylaxis such as disodium cromoglycate. When disodium cr~oglycate is used we prefer it to be dried before use. When the medicament is to be inhaled we prefer that it has a mass median diameter in the range 0.01 to 10 microns. ~e prefer the finely divided material to comprise rom 0.05 to 15,, preferably from 0.1 to 10.0 and m~st preferably from 1 to 5~0 of the dispersionO Further pro~ellant 12 `~ and/or propellant 114 (appropriately cooled, e.g. to -50C) may be t added to the original dispersion or the original dispersion containing the finely divided material which it is desired to dispense.
According to our invention we also provide a dispersion or suspension of lecithi~ or a sorbitan or sorbltol ester in a mixture of propellant 12 and propellant 114, the dispersion or suspension containin~ no propellant 11, and preferably containing no other propellants whatsoever.
l~e prefer the ratio of propellant 12 to propellant 114 in the inal mixture to be in the range 2 to 1:1, and preferably about lt5:1 by weight; i.e. we prefer an excess of propellant 12 over propellant 114.
We prefer the dispersion or suspension of the surfactant in the ; 25 final mixture of pro~ellants 12 and 114 to contain from 0.15 to ~' _ 4 _ 0~/C/244 , ` ,~
~L~L3L~2~ '7
~- Leci~hin and various esters, notably sorbitan esters, e.g.
sorbitan oleates such as sorbitan sesquioleate ('Arlacel C'~*
sorbitan mono-oleate ~'Span 80')*and sorbitan trioleate ('Span 85')*, - sorbitan monolaurate3 polyoxyethylene sor~itol pentaoleate and polyoxyethylene sorbitol tetraoleate, have for some tirr.e been ;- known as surfactants fo~ use in pressure pack formulations ofmaterials and in particular for use in pressure pack formulations of finely divided medicaments. The formulation of these surfactants ., .
has invol~ed the use of p~opellant 11 (trichloromonofluoromethane).
Propellznt 11 has h~rever certain undesirable properties. The common practice in pressure pack nanufactu~e is to make a so called 'concentrate' or 'nucleus suspension' of the compound to be dispensed, e.g. the medicament, and one of the above surfactants ,-: . . .
in either propellant 11 or propellant 114 (1,2-dichloro-1,1,2~2-tctrafluoroethane). These concentrates may, because of the relatively high boiling point of the propellants, be handled at, or just bel~.Y~ ~oom temperature. It has however been found that lecithin and the esters mentioned above are extremely difficult to disperse in propellant114 and ~hese surfactants have therefore been dispersed in propellant 11. Other propellants of lower `~ boiling point have not been used because these surfactants ~ould not dissolve in these other propellants at the tow temperatures *trade mark ' 1 , ~
6'7 involved and furthermore would be solid at these low tempera~ures.
We have now found that lecithin and the above esters can be made into stable dispersions in propellant 12 (dichlorodifluoro-methane).
According to our invention ~e provide a dispersion or suspension of lecithin or a sorbitan or sorbltol ester in propellant 12, the dispersion or suspension containing substantially no propellant 11.
The dispersion may, if desired contain up to 25~ by weight of propellant 114, but preferably oontains no propellants other than ,: .
propellant 12.
The dispersion may be made by adding the lecithin or the - sorbitan or sorbitol ester to the propellant 12 ~or to a mixture of propellants 12 and 114) at a temperature of below about -30C, e.g. at 40C, using a high dispersion mixer. The dispersion .i.
- 15 preferably comprises less than ~.0%, e.g. from 0.2 to 2.0~ w/w of the leicithin or of the sorbitan or sorbitol ester. In ma~ing the suspension the surfactan~ solidifies, but is readily dispersed as small discrete particles in the propellant 12 tor the mixture of propellants 12 and 114). The resulting dispersions are usually stable for at least 30 minutes.
The dispersion of the surfactant m the propellant lZ ~or the mixture of propellants 12 and 1143 can be mixed wnth the finely divided material which it is desired to dispense ~rom the pressure pack. Suitabi~ ~mely di~ided materials include medicaments and notably inhalation medicaments, e.g. bronchodilators such as '' .
'7 isoprenaline, orciprenaline, terbutalene, rimiterol, fenoterol, carbutarol or salbutamol or a pharmaceutically acceptable salt of any one the~eof; topical steroids such as beclomethasone dipropionate, betamethasone valerate or triamcinolone acetonide;
- S and compounds which prevent the release of mediators of anaphylaxis such as disodium cromoglycate. When disodium cr~oglycate is used we prefer it to be dried before use. When the medicament is to be inhaled we prefer that it has a mass median diameter in the range 0.01 to 10 microns. ~e prefer the finely divided material to comprise rom 0.05 to 15,, preferably from 0.1 to 10.0 and m~st preferably from 1 to 5~0 of the dispersionO Further pro~ellant 12 `~ and/or propellant 114 (appropriately cooled, e.g. to -50C) may be t added to the original dispersion or the original dispersion containing the finely divided material which it is desired to dispense.
According to our invention we also provide a dispersion or suspension of lecithi~ or a sorbitan or sorbltol ester in a mixture of propellant 12 and propellant 114, the dispersion or suspension containin~ no propellant 11, and preferably containing no other propellants whatsoever.
l~e prefer the ratio of propellant 12 to propellant 114 in the inal mixture to be in the range 2 to 1:1, and preferably about lt5:1 by weight; i.e. we prefer an excess of propellant 12 over propellant 114.
We prefer the dispersion or suspension of the surfactant in the ; 25 final mixture of pro~ellants 12 and 114 to contain from 0.15 to ~' _ 4 _ 0~/C/244 , ` ,~
~L~L3L~2~ '7
2.0~, preferably 0.2 to 1.2% by weight of lecithin or of the sorbitan or sorbitol ester. ~e also prefer such dispersions or suspensions to contain from O.OS to 2.0~, and preferably from 0.2 to 2.0~, by weight of medicament~ e.g. disodium cromoglycate.
Dispersions of from 0.2 to 2 parts by wei~ht of sorbitan ester in a mixture of from S0 to 70 parts by weight of propellant 12 and from 50 to 30 parts by ~eight of propellant 114 are stable for at least 16 hours at a temperature o -60C.
We particularly prefer dispersions in which the surfactant ,~
is a sorbitan ester, e.g. sorbitan trioleate ('Span 80'). Il~en lecithin is used we prefer it to be vegetable, e,g. soya, lecithin The compositions according to the invention preferably contain less than 1.0~, more preferably less than 0.5~ and most preferably less than 0.2~ by weight of water.
As a particular facet of our in~ention we pro~ide a mixture comprising a sorbitan ester, e.g. sorbitan trioleate, disodium cromoglycate, propellant 12, propellant 114 and no propellant 11.
Certain compositions according to the invention are advantageous in that they either give a higher proportion of fine particles in the aerosol cloud produced, or that they can be used to produce such formulations, as co~pared to equivalent co~positions ;~ containing propellant 11. A suitable method of determining the proportion of fine particles produced in an aerosol cloud is described In J Pharm, Pharmac. 1973, 25, Suppl. 32P-36P.
", ., .
, - 6 - ~ '7 ..~, The inve~tion is illustrated, but in no way limited by the ` following Exa~ples.
Example 1 ! Mbthod :
The sorbitan ester is dispersed in up to half ~le propellant 12 at -40C while stirrLng with a high dispersion mixer. The dry ~'? drug ~s added to the resulting dispersion and disperses In it very readily. The balance of the propellant lZ is then added at -50C, followed by the propellant 114 also cooled to -50C. The resulting mixtures are then filled into vials onto which valves, e.g. metering valves, are subsequently crimped.
Ingredients Table ~ w/w ~ w/w 15 Dried nicronised disodium cromoglycate0.3605 1.4420 Sorbitan trioleate 0.2500 1.0000 Propellant 11439.755839.0232 Propellant 1259.633758.5348 . .
Stability Batches of vials fitted with metering val~es and containing the above fonmulations were stored at 5C, 25C and 37&
respectively for a period of 12 months. Two further batches of : vials were stored at respectively ~a3 temperatures which varied from 15C to 37& , and (b~ at a temperature of 45 & for a period ,; , ';' ' ''' . ~, .
. . .
'. ' . -~ 7 ~ ~L3L~L~ 7 .~.
of 6 months. No change in (a~ the amount of disodium cromoglycate dispersed per shot, (b) the content of fine particles in the cloud or (c3 the crystal size o~ ~he s~dium crom~lycate was observed cver the period ~f observation.
,r 5 Exam~le 2 Using the method described in Example 1 the following compositions were made and filled into vials.
(a) Beclomethas _e dipropionate, 50 ~g/dose ~ w/w ~eclomethasone dipropionate, micronised 0.0729 Sorbitan m~nolaurate 0.2187 Propellant 114 29.9125 Propellant 12 69.7959 Cb) Betamethasone valerate 100 ~/dose lS ~ ~J/W
Betamethason0 valerate, micronised0.1442 Sorbitan sesquioleatei 0.3605 Propellant 114 39.79Bl Propellant 12 59.6972 (c) Orciprenaline sulphate, 750 ~ ~/dose ~ w/w Orciprenaline sulphate, micronised1.0707 Sorbitan monolaurate 1.9985 Propellant 114 48.4654 Prope~llant 12 - 48.4654 '' ~ - 7 -. ~ _ , ... . . . .
- , 8 ~L~L~
,, (d) Terbutalene sulPhate 2C0 ~/dose /w Terbulalene sulphate, micronised 0.2869 Sorbitan monoGleate~ 0.5739 Propellant 114 44.6126 Propellant 12 54.5266 ~e) Rimiterol hYdrobromide 200 /dose ...._ , ~L4g , % w/w ~imiterol hydrobromide, micronised 0.2900 Sorbitan trioleate0.7252 Propellant 11434.6447 Propellant 12 64.3401 . (f) Salbu~a~,ol sulphate, 120.5 ~ g/dose (equivalent to 100~ g/dose salbutamol) % w/w Salbutamol sulphate, micronised0.1738 - Snrbitan monooleate 0.3309 : Propellant 114 39.7981 Propellant 12 59.6972 , .
(g) Fenoterol hydrobromide 200 ~ g/dose % t~/W
Fenoterol hydrobromide, micronised 0.2869 Sorbitan ses~uioleate 0.7174 Propellant 114 44.5481 Propellant 12 54.4476 ' ._ ' .
08~C/244 ~, .
(h) Isoprenaline hydrochloride 160 ~ ~Jdose and phenylephrine ~ w/w Isoprenaline llydrochloride, micronised 0.2320 Phenylephrine bitatrate, micro~ised 0.3481 Sorbitan trioleate 0.7977 Propellant 114 34.5178 Propellant 12 64.1044 , "~
. . .
: 20 ."
_ 9:
., , _. .
. . .
Dispersions of from 0.2 to 2 parts by wei~ht of sorbitan ester in a mixture of from S0 to 70 parts by weight of propellant 12 and from 50 to 30 parts by ~eight of propellant 114 are stable for at least 16 hours at a temperature o -60C.
We particularly prefer dispersions in which the surfactant ,~
is a sorbitan ester, e.g. sorbitan trioleate ('Span 80'). Il~en lecithin is used we prefer it to be vegetable, e,g. soya, lecithin The compositions according to the invention preferably contain less than 1.0~, more preferably less than 0.5~ and most preferably less than 0.2~ by weight of water.
As a particular facet of our in~ention we pro~ide a mixture comprising a sorbitan ester, e.g. sorbitan trioleate, disodium cromoglycate, propellant 12, propellant 114 and no propellant 11.
Certain compositions according to the invention are advantageous in that they either give a higher proportion of fine particles in the aerosol cloud produced, or that they can be used to produce such formulations, as co~pared to equivalent co~positions ;~ containing propellant 11. A suitable method of determining the proportion of fine particles produced in an aerosol cloud is described In J Pharm, Pharmac. 1973, 25, Suppl. 32P-36P.
", ., .
, - 6 - ~ '7 ..~, The inve~tion is illustrated, but in no way limited by the ` following Exa~ples.
Example 1 ! Mbthod :
The sorbitan ester is dispersed in up to half ~le propellant 12 at -40C while stirrLng with a high dispersion mixer. The dry ~'? drug ~s added to the resulting dispersion and disperses In it very readily. The balance of the propellant lZ is then added at -50C, followed by the propellant 114 also cooled to -50C. The resulting mixtures are then filled into vials onto which valves, e.g. metering valves, are subsequently crimped.
Ingredients Table ~ w/w ~ w/w 15 Dried nicronised disodium cromoglycate0.3605 1.4420 Sorbitan trioleate 0.2500 1.0000 Propellant 11439.755839.0232 Propellant 1259.633758.5348 . .
Stability Batches of vials fitted with metering val~es and containing the above fonmulations were stored at 5C, 25C and 37&
respectively for a period of 12 months. Two further batches of : vials were stored at respectively ~a3 temperatures which varied from 15C to 37& , and (b~ at a temperature of 45 & for a period ,; , ';' ' ''' . ~, .
. . .
'. ' . -~ 7 ~ ~L3L~L~ 7 .~.
of 6 months. No change in (a~ the amount of disodium cromoglycate dispersed per shot, (b) the content of fine particles in the cloud or (c3 the crystal size o~ ~he s~dium crom~lycate was observed cver the period ~f observation.
,r 5 Exam~le 2 Using the method described in Example 1 the following compositions were made and filled into vials.
(a) Beclomethas _e dipropionate, 50 ~g/dose ~ w/w ~eclomethasone dipropionate, micronised 0.0729 Sorbitan m~nolaurate 0.2187 Propellant 114 29.9125 Propellant 12 69.7959 Cb) Betamethasone valerate 100 ~/dose lS ~ ~J/W
Betamethason0 valerate, micronised0.1442 Sorbitan sesquioleatei 0.3605 Propellant 114 39.79Bl Propellant 12 59.6972 (c) Orciprenaline sulphate, 750 ~ ~/dose ~ w/w Orciprenaline sulphate, micronised1.0707 Sorbitan monolaurate 1.9985 Propellant 114 48.4654 Prope~llant 12 - 48.4654 '' ~ - 7 -. ~ _ , ... . . . .
- , 8 ~L~L~
,, (d) Terbutalene sulPhate 2C0 ~/dose /w Terbulalene sulphate, micronised 0.2869 Sorbitan monoGleate~ 0.5739 Propellant 114 44.6126 Propellant 12 54.5266 ~e) Rimiterol hYdrobromide 200 /dose ...._ , ~L4g , % w/w ~imiterol hydrobromide, micronised 0.2900 Sorbitan trioleate0.7252 Propellant 11434.6447 Propellant 12 64.3401 . (f) Salbu~a~,ol sulphate, 120.5 ~ g/dose (equivalent to 100~ g/dose salbutamol) % w/w Salbutamol sulphate, micronised0.1738 - Snrbitan monooleate 0.3309 : Propellant 114 39.7981 Propellant 12 59.6972 , .
(g) Fenoterol hydrobromide 200 ~ g/dose % t~/W
Fenoterol hydrobromide, micronised 0.2869 Sorbitan ses~uioleate 0.7174 Propellant 114 44.5481 Propellant 12 54.4476 ' ._ ' .
08~C/244 ~, .
(h) Isoprenaline hydrochloride 160 ~ ~Jdose and phenylephrine ~ w/w Isoprenaline llydrochloride, micronised 0.2320 Phenylephrine bitatrate, micro~ised 0.3481 Sorbitan trioleate 0.7977 Propellant 114 34.5178 Propellant 12 64.1044 , "~
. . .
: 20 ."
_ 9:
., , _. .
. . .
Claims (8)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:-
1. An inhalation composition comprising a dispersion or suspension of an effective amount of disodium cromoglycate and an effective amount of lecithin or a sorbitan or sorbitol ester in a propellant mixture comprising di-chlorodifluoromethane and 1,2-dichloro-1,1,2,2-tetra fluoroethane, the ratio of dichlorodifluoromethane to 1,2-dichloro-1,1,2,2-tetrafluoroethane in said mixture being in the range from 2:1 to 1:1 by weight, said dis-persion or suspension containing no trichloromonofluoro-methane.
2. A composition according to Claim 1, wherein the di-sodium cromoglycate has a mass median diameter of 0.01 to 10 microns.
3. A composition according to Claim 1 or Claim 2 compris-ing from 0.15 to 2.0% by weight of lecithin or of said sorbitan or sorbitol ester.
4. A composition according to Claim 1 or Claim 2, com-prising from 0.05 to 2.0% by weight of disodium cromo-glycate.
5. A composition according to Claim 1 or Claim 2, wherein said sorbitan ester is sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, or sorbitan trioleate.
6. A composition according to Claim 1 or Claim 2 comprising less than 1% by weight of water.
7. A composition according to Claim 1 or Claim 2, wherein said propellant mixture contains no propellant other than said dichlorodifluoromethane and said 1,2-dichloro-1,1,2,-2-tetrafluoroethane.
8. A method of making a composition according to Claim 1 or Claim 2, which comprises dispersing the lecithin or sorbitan or sorbitol ester and the disodium cromoglycate in dichlorodifluoromethane and mixing the resulting dis-persion with 1,2-dichloro-1,1,2,2-tetrafluoroethane.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB30169/77 | 1977-07-19 | ||
| GB3016977 | 1977-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1112567A true CA1112567A (en) | 1981-11-17 |
Family
ID=10303374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA307,480A Expired CA1112567A (en) | 1977-07-19 | 1978-07-17 | Disodium cromoglycate self-propelling compositions |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5435209A (en) |
| AU (1) | AU522792B2 (en) |
| BE (1) | BE869055A (en) |
| CA (1) | CA1112567A (en) |
| CH (1) | CH627075A5 (en) |
| DE (1) | DE2831419A1 (en) |
| FR (1) | FR2397833A1 (en) |
| HK (1) | HK51585A (en) |
| IE (1) | IE47128B1 (en) |
| IL (1) | IL55161A (en) |
| IT (1) | IT1158890B (en) |
| MY (1) | MY8400252A (en) |
| NL (1) | NL7807625A (en) |
| NZ (1) | NZ187894A (en) |
| SE (1) | SE443087B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284287B1 (en) | 1994-07-16 | 2001-09-04 | Asta Medica Ag | Particulate formulation for administration by inhalation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| HU205249B (en) * | 1990-11-09 | 1992-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing suspensive aerosole composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB367276A (en) * | 1931-06-20 | 1932-02-18 | Schmidt Sche Heissdampf | Improvements in or relating to independently fired steam superheaters |
| BE555319A (en) * | 1956-03-21 | 1900-01-01 | ||
| BE556587A (en) * | 1957-01-31 | 1957-04-11 | ||
| GB1144905A (en) * | 1965-03-25 | 1969-03-12 | Fisons Pharmaceuticals Ltd | Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof |
| US3513104A (en) * | 1965-03-26 | 1970-05-19 | Colgate Palmolive Co | Self-propelling powder compositions |
| US3560507A (en) * | 1968-02-27 | 1971-02-02 | Millmaster Onyx Corp | Quaternary ammonium alkenyl succinates |
| GB1384895A (en) * | 1971-01-25 | 1975-02-26 | Colgate Palmolive Co | Fabric conditioning |
| DE2151706B1 (en) * | 1971-10-18 | 1973-05-03 | Cegla, Ulrich, Dr med , 600 0 Frank fürt Niederrad | Tantalum-contg x-ray contrast agents - in aerosol form for bronchography |
| IL44022A0 (en) * | 1973-01-23 | 1974-05-16 | Fisons Ltd | Novel salts of anti-inflammatory quinoline derivatives,their preparation and pharmaceutical compositions containing them |
| IT1039699B (en) * | 1975-07-03 | 1979-12-10 | Prephar | SPERMICIDE COMPOSITION BASED ON BENZISOTHIAZOLIC DERIVATIVES |
| GB1562901A (en) * | 1976-01-30 | 1980-03-19 | Fisons Ltd | Disodium cromoglycate |
| IL51314A (en) * | 1976-01-30 | 1980-03-31 | Fisons Ltd | Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it |
| GB2001334B (en) | 1977-07-19 | 1982-03-03 | Fisons Ltd | Pressurised aerosol formulation |
| GB1590126A (en) | 1977-11-23 | 1981-05-28 | Booth B H | Method of bulking yarns |
-
1978
- 1978-07-14 AU AU38057/78A patent/AU522792B2/en not_active Expired
- 1978-07-17 NL NL7807625A patent/NL7807625A/en active Search and Examination
- 1978-07-17 CA CA307,480A patent/CA1112567A/en not_active Expired
- 1978-07-17 FR FR7821172A patent/FR2397833A1/en active Granted
- 1978-07-17 IE IE1432/78A patent/IE47128B1/en not_active IP Right Cessation
- 1978-07-17 BE BE189326A patent/BE869055A/en not_active IP Right Cessation
- 1978-07-18 SE SE7807934A patent/SE443087B/en not_active IP Right Cessation
- 1978-07-18 IT IT25845/78A patent/IT1158890B/en active Protection Beyond IP Right Term
- 1978-07-18 DE DE19782831419 patent/DE2831419A1/en active Granted
- 1978-07-18 JP JP8682578A patent/JPS5435209A/en active Granted
- 1978-07-18 CH CH774178A patent/CH627075A5/en not_active IP Right Cessation
- 1978-07-18 NZ NZ187894A patent/NZ187894A/en unknown
- 1978-07-18 IL IL55161A patent/IL55161A/en unknown
-
1984
- 1984-12-30 MY MY252/84A patent/MY8400252A/en unknown
-
1985
- 1985-07-04 HK HK515/85A patent/HK51585A/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284287B1 (en) | 1994-07-16 | 2001-09-04 | Asta Medica Ag | Particulate formulation for administration by inhalation |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2831419A1 (en) | 1979-02-01 |
| AU3805778A (en) | 1980-01-17 |
| IT1158890B (en) | 1987-02-25 |
| FR2397833B1 (en) | 1982-06-25 |
| JPS6411615B2 (en) | 1989-02-27 |
| SE7807934L (en) | 1979-01-20 |
| MY8400252A (en) | 1984-12-31 |
| NZ187894A (en) | 1984-05-31 |
| IE47128B1 (en) | 1983-12-28 |
| AU522792B2 (en) | 1982-06-24 |
| JPS5435209A (en) | 1979-03-15 |
| NL7807625A (en) | 1979-01-23 |
| IL55161A0 (en) | 1978-09-29 |
| FR2397833A1 (en) | 1979-02-16 |
| HK51585A (en) | 1985-07-12 |
| IE781432L (en) | 1979-01-19 |
| BE869055A (en) | 1979-01-17 |
| IL55161A (en) | 1981-12-31 |
| CH627075A5 (en) | 1981-12-31 |
| DE2831419C2 (en) | 1989-01-05 |
| SE443087B (en) | 1986-02-17 |
| IT7825845A0 (en) | 1978-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4405598A (en) | Composition for treating asthma | |
| EP1102579B1 (en) | Medicinal aerosol formulations | |
| EP1372608B1 (en) | Medical aerosol formulations | |
| EP1100465B1 (en) | Medicinal aerosol formulations | |
| JP3497161B2 (en) | New propellant mixtures and their use in pharmaceutical formulations | |
| DE69915144T2 (en) | Aerosol pressure dosing devices and aerosol pharmaceutical compositions | |
| EP1014943B1 (en) | Medical aerosol formulations | |
| DE2703119C2 (en) | ||
| CA2074495C (en) | Propellant compositions | |
| CA1264297A (en) | Drug-containing chlorofluorocarbon aerosol propellent formulations | |
| AU649702B2 (en) | Aerosol drug formulations | |
| CA2062854A1 (en) | Pharmaceutical aerosol formulations | |
| JPH02200627A (en) | Medical aerosol preparation | |
| SI9110155A (en) | Novel vehicle gas mixtures and their use in medical preparations | |
| EP0605483B1 (en) | Propellant for aerosols and dosing aerosols | |
| GB2122087A (en) | Topical corticosteroid preparation | |
| CA1112567A (en) | Disodium cromoglycate self-propelling compositions | |
| US4933168A (en) | Stable, crystalline flunisolide | |
| JPH04210918A (en) | Atropine-salbutamol aerosol agent | |
| AT402014B (en) | SUSPENSION SAEROSOL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF | |
| EP1161225B1 (en) | Metered dose inhalers with isobutane as propellant | |
| TW202128159A (en) | Pharmaceutical composition of aerosol inhalant containing indacaterol and preparation method thereof | |
| DE19908210A1 (en) | Aerosol compositions, which are stable and are free of hydrofluorocarbons, include a medicament, a sorbitan trifatty acid ester surfactant and propane as propellant | |
| CA1083963A (en) | Use of flunisolide to treat respiratory diseases | |
| CA1176171A (en) | Compositions containing the disodium salt of 1,3- bis(2-carboxychromon-5-yloxy)-propan-2-ol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |